Screener
Opko Health OPK Diagnostics — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Opko Health in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Opko Health’s 10-Q, filed July 27, 2026.
- Filed
- Jul 27, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-318090
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| Depreciation and amortization: | ||||
| Pharmaceutical | $18,511 | $18,142 | $36,770 | $35,930 |
| Diagnostics | 3,883 | 4,885 | 7,810 | 10,584 |
| Corporate | 15 | — | 29 | — |
| $22,409 | $23,027 | $44,609 | $46,514 | |
| Revenues: | ||||
| United States | $88,809 | $114,884 | $172,313 | $231,091 |
| Ireland | 41,663 | 11,742 | 51,343 | 17,221 |
Item 1. Financial Statements
FAQ
- What is Opko Health's diagnostics — D&A?
- Opko Health (OPK) reported diagnostics — D&A of $3.88M in Q2 2026.
- How has Opko Health's diagnostics — D&A changed year-over-year?
- Opko Health's diagnostics — D&A decreased by 20.5% year-over-year, from $4.89M to $3.88M.
- What is the long-term trend for Opko Health's diagnostics — D&A?
- Over 4 years (2021 to 2025), Opko Health's diagnostics — D&A has grown at a -22.0% compound annual growth rate (CAGR), from $52.29M to $19.37M.
- What does diagnostics — D&A mean?
- This metric represents the non-cash expense allocated to the Diagnostics segment for the wear and tear of tangible assets and the systematic write-down of intangible assets over their useful lives. It reflects the capital intensity required to maintain the diagnostic testing infrastructure and technology platforms.
Ask your AI about Opko Health's diagnostics — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude